GEOVAX LABS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
GEOVAX LABS, INC. (GOVX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $1.18 per share for the 6-month period ending 2026-06-30, per its S-1 filed 2026-09-17.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-09-17
- GEOVAX LABS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- GEOVAX LABS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $10.98, a 282.58% increase from fiscal 2021.
- GEOVAX LABS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $2.87, a 156.25% increase from fiscal 2020.
- GEOVAX LABS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2020 was $1.12.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|
| 2026-06-30 | $1.18 S-1 · filed 2026-09-17 | |||
| 2025-12-31 | $61.05 S-1 · filed 2026-09-17 | |||
| 2024-12-31 | $55.39 S-1 · filed 2026-09-17 | $2.22 10-K · filed 2025-03-27 | ||
| 2023-12-31 | $0.00 10-K · filed 2025-03-27 | |||
| 2022-12-31 | $10.98 10-K · filed 2024-02-29 | $0.73 10-K · filed 2023-03-23 | ||
| 2021-12-31 | $2.87 10-K · filed 2023-03-23 | |||
| 2020-12-31 | $1.12 10-K · filed 2022-03-09 | |||
| 2018-12-31 | $0.02 10-K · filed 2019-03-26 | |||
| 2017-12-31 | $0.04 10-K · filed 2019-03-26 | |||
| 2016-12-31 | $0.05 10-K · filed 2019-03-26 | |||
| 2015-12-31 | $0.09 10-K · filed 2018-03-23 | |||
| 2014-12-31 | $0.14 10-K · filed 2017-03-24 | |||
| 2013-12-31 | $0.43 10-K · filed 2016-03-16 | |||
| 2012-12-31 | $0.59 10-K · filed 2015-03-20 | |||
| 2011-12-31 | $0.79 10-K · filed 2014-03-14 | |||
| 2010-12-31 | $2.95 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B |